Women hospitalized with coronary artery disease are less likely to receive optimal care at discharge compared with men and African Americans have an elevated risk of mortality compared with white patients, study finds.
A large nationwide sample of more than 49,000 older Americans hospitalized with coronary artery disease found that disparities in mortality with respect to sex and race/ethnicity exist across the nation.
The study found women were less likely to receive optimal care at discharge compared with men and that African Americans had an elevated risk of mortality compared with white patients. However, the African American mortality disparity could not be accounted for by differences in the quality of care measured. No significant differences were observed in care or outcomes by geographic region.
The study, published in Circulation, followed patients 65 years of age and older who were admitted to 366 US hospitals from 2003 to 2009 as part of the Get With the Guidelines Coronary Artery Disease registry. The outcome tracked was 3-year all-cause mortality. Quality-of-care performance measures included aspirin within 24 hours, aspirin upon hospital discharge, beta-blocker on hospital discharge, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for patients with low-ejection fraction on hospital discharge, smoking cessation counseling, and lipid-lowering medications.
Compared with men, women were less likely to receive optimal care (odds ratio [OR], 0.92; 95% CI: 0.88-0.95, P <.0001) and were more likely to have higher mortality if they received suboptimal care. Approximately 69% of the sex disparity may be reduced by providing optimal quality of care to women, researchers said. They also found that quality of care did not differ across racial/ethnic groups or geographic regions. Although African Americans were more likely to die than whites (OR, 1.33; 95% CI: 1.21-1.46; P <.0001), the disparity persisted regardless of the quality of care received.
Women tended to present with hypertension and heart failure at hospital admission more often than men, were less likely to receive lipid-lowering medications and in-hospital procedures than men, and were less likely than men to receive optimal care at discharge. Women had a 1.20-fold higher 3-year mortality rate than men, but the disparity was lessened after adjustment for demographic and medical characteristics. The researchers identified a significant interaction between sex and quality of care measures on mortality, however. Compared with men, women had higher odds of mortality if they received suboptimal care, and that sex disparity disappeared with optimal care.
Compared with white patients, African Americans had a higher prevalence of diabetes, hypertension, and dialysis but were similar regarding quality of care measures received. African American patients were at higher risk for mortality than white patients—a disparity that persisted regardless of the quality of care received.
The study authors noted that it is largely unknown whether and how differences in quality of care could explain or alleviate the sex mortality gap, but their results suggest that providing optimal care to cardiac patients could yield large gains in reducing sex-related disparities.
“This highlights the importance of targeting and tailoring quality of care programs on specific high-risk populations,” the authors concluded.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More